Souhaitez-vous accéder aux communiqués récents ?

Oslo, Norway, 18 August 2014: Photocure ASA (OSE: PHO), a specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, announces today that Photocure and Salix...

Photocure will present its second quarter report on Tuesday 26 August 2014 at Hotel Continental, Oslo, Norway. The presentation will begin at 08:30 (CET) and representatives from the company will...

Oslo, Norway, 10th July 2014:  Photocure ASA (OSE: PHO), a specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, is pleased to note that updated expert...

Bill makes most up-to-date cancer treatment available to patients; requires fair payment policy for hospitals Oslo, Norway, 25 June 2013:  Photocure ASA (OSE: PHO), a specialty pharmaceutical...

Oslo, Norway, 27 May, 2014. The Annual General Meeting in Photocure ASA took place on 27 May, 2014. A new Board of Directors was elected and consists of the following members until next Annual...

  This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. ...

Oslo, Norway, 7 May 2014: Photocure (OSE: PHO), a Norwegian specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, announces its results for the first...

Please find enclosed an invitation to the annual general meeting at Photocure ASA on 27 May 2014 at 17:00 hours (CET). The meeting will take place at Photocure's head office at Hoffsveien 4, 2nd...

Photocure will present its first quarter report on Wednesday 7 May 2014 at Hotel Continental, Oslo, Norway. The presentation will begin at 08:30 (CET) and representatives from the company will be...

The Annual report 2013 for Photocure ASA is enclosed in English and Norwegian. The Annual report is also available on the company's website http://www.photocure.com/Investor-relations/. For further...